Not Yet RecruitingNot Applicable

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

120 participantsStarted 2024-07-01

Plain-language summary

The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participate din the study in 2017 to undergo follow-up examinations in 2024, in order to allow comparisons of current results with baseline data from 2017.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Permanently living \>2500 m * Written informed consent Exclusion Criteria: * Highlanders who cannot follow the study investigations, * Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years. * Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

What they're measuring

Change in pulmonary artery pressure in highlanders

Timeframe: Year 2017 to 2024

Trial details

NCT IDNCT06489730

SponsorUniversity of Zurich

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

Contact for this trial

Silvia Ulrich, Prof. Dr.

+41442552220 silvia.ulrich@usz.ch

View on ClinicalTrials.gov More High Altitude Pulmonary Hypertension trials